A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-Experienced Subjects.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-Experienced Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 23 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Planned end date (1 Aug 2010) added as reported by ClinicalTrials.gov
    • 09 Jul 2009 Actual initiation date (1 Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top